Clinical Trials

Phase 1 Active not recruiting

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01479842 2025-10-15

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

48 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Phase 1/2 Active not recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04446962 2025-09-25

LOC-R01

118 enrolled

CNSLymphoid

Lymphoma, Neurologic Manifestations, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms

NCT03424122 2025-08-21

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

50 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02303392 2025-06-10

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

LymphoidOther hematologic neoplasm

34 enrolled 14 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03939182 2025-04-25

Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

15 enrolled

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01855750 2025-02-04

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Phase 3 Completed

838 enrolled 16 charts

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02743546 2025-02-03

Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma

Phase 1 Withdrawn

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03129828 2024-12-13

ImbruVeRCHOP

Phase 1/2 Completed

38 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT02692248 2024-10-10

Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT

Phase 2 Completed

64 enrolled 17 charts

Lymphoma, Large B-Cell, Diffuse

NCT03136497 2024-09-23

A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 1 Terminated

10 enrolled 14 charts

Lymphoma, Large B-Cell, Diffuse

NCT03310619 2024-04-04

PLATFORM

Phase 1/2 Completed

62 enrolled 41 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03684694 2024-02-06

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Phase 1/2 Terminated

136 enrolled 33 charts

Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03399513 2024-01-05

R-CHOEP-brut

Phase 2 Completed

40 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03876028 2023-01-31

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

Phase 1 Terminated

10 enrolled

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02756247 2022-10-10

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

37 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02077166 2022-02-04

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 1/2 Completed

138 enrolled 22 charts

Lymphoma, Large B-Cell, Diffuse

NCT03949062 2021-02-17

Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL

30 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04025593 2020-11-19

Biomarker Guided Treatment in DLBCL

128 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT02950220 2019-07-30

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

2 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02747732 2019-04-23

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

72 enrolled

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02219737 2018-01-26

Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

26 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT01325701 2017-03-31

Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 2 Completed

78 enrolled 10 charts

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02955628 2017-02-14

RICE-ibrutinib in Relapsed DLBCL

34 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT02780830 2016-09-15

INHIBITOR

Phase 1 Withdrawn